UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
(Date of earliest event reported):
May 01, 2014
Cardigant Medical Inc.
(Exact name of Registrant as specified in its charter)
Delaware, 333-176329, 26-4731758
(State or other jurisdiction
of incorporation) (Commission
File Number) (IRS Employer
Identification)
1500 Rosecrans Avenue, St 500
Manhattan Beach, CA 90266
(Address of principal executive office and zip code)
(310) 421-8654
(Registrant's telephone number, including area code)
Check the appropriate box bellow if the 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under
any of the following provisions:
Written communication pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c)).
Item 4.01 Changes in Registrant’s Certifying Accountant.
Due to the partner rotation rules and regulations of the U.S. Securities and Exchange Commission and Sarbanes-Oxley Act of 2002 (the "Partner Rotation Rules"), the Board of Directors’ of Cardigant Medical Inc. (the “Company”) is announcing the resignation of its independent registered accounting firm and announcing the appointment of its successor independent registered accounting firm. The Partner Rotation Rules limit the lead audit partner's audit services to a term of five years. The Company has accepted the resignation of Jonathon P. Reuben, An Accountancy Corporation and has approved the appointment of Farber Hass Hurley LLP to serve as the Company’s new independent registered accounting firm effective May 01, 2014.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Cardigant Medical Inc.
By: /s/ Jerett Creed
Jerett Creed
Title: President and CEO
Dated: May 01, 2014